Every breath sustains life, though few recognize how routine decisions shape respiratory wellness. Innovative interventions, ...

The fungal lung infection has historically been most common around the Central Valley — but that's now changed as cases have ...

In a significant research advancement that may help inform treatment strategies for millions of patients worldwide, a ...

Jonathan Thompson, MD, MS, emphasized that broader molecular testing in early-stage non–small cell lung cancer (NSCLC) is essential to guide perioperative treatment decisions, while selective ...

Merck MRK announced that the FDA has granted the Breakthrough Therapy designation (BTD) to its B7-H3-directed DXd antibody-drug conjugate (ADC), ifinatamab deruxtecan (I-DXd), for treating adult ...

An executive cites the company's 140-year track record as it faces federal action on drug pricing and industry tariffs.

The FDA granted breakthrough therapy designation to Ifinatamab deruxtecan for some with extensive-stage small cell lung ...

The A5 nanobody is around 10 times smaller than conventional antibodies, helping it to penetrate deep into tissues. Crucially, it can bind selectively to cancer cells, leading to a reduction of more ...

BC, AOCNP, explained that adverse effects are common among the available antibody-drug conjugates in breast cancer.

In 2021, ATYR completed a phase 1b/2a trial in pulmonary sarcoidosis, and have since started a phase 3 trial. Currently the ...

Rein Therapeutics ('Rein') (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines ...

A colourless liquid with a sharp odour, hydrogen peroxide occurs naturally in tiny amounts in human tissue (as a by-product ...